Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97
Drug Regulation01:25

Drug Regulation

3.0K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.0K
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

343
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
343
Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

706
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
706
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

430
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
430
Decision Making: P-value Method01:09

Decision Making: P-value Method

5.8K
The process of hypothesis testing based on the P-value method includes calculating the P- value using the sample data and interpreting it.
First, a specific claim about the population parameter is proposed. The claim is based on the research question and is stated in a simple form. Further, an opposing statement to the claim  is also stated. These statements can act as null and alternative hypotheses:  a null hypothesis would be a neutral statement while the alternative hypothesis can...
5.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hospitalization for Malignant Arrhythmias Following Initiation of Donepezil: A Retrospective Cohort Study.

Pharmacoepidemiology and drug safety·2026
Same author

Estimating the daily milligrams of morphine equivalent of illicit fentanyl use in Los Angeles: Clinical and epidemiological implications.

Drug and alcohol dependence·2026
Same author

Geographic variation and neighbourhood correlates of mental health-related hospitalizations and emergency department visits in children and youth during the COVID-19 pandemic: a population-based study.

Frontiers in child and adolescent psychiatry·2026
Same author

Opioid Toxicity Following Concomitant Use of Macrolide Antibiotics with Fentanyl, Hydromorphone, or Oxycodone: A Population-Based Study.

Clinical pharmacology and therapeutics·2026
Same author

Estimating the Daily Milligrams of Morphine Equivalent of Illicit Fentanyl Use in Los Angeles: Clinical and Epidemiological Implications.

medRxiv : the preprint server for health sciences·2026
Same author

Association between COVID-19 vaccination and sudden death in apparently healthy younger individuals: A population-based case-control study.

PLoS medicine·2026

Related Experiment Video

Updated: May 2, 2026

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery
09:38

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery

Published on: April 14, 2016

14.0K

Painful decision-making at FDA.

Lewis S Nelson1, Jeanmarie Perrone, David N Juurlink

  • 1New York University School of Medicine, Emergency Medicine , New York, NY , USA lewis.nelson@nyumc.org.

Expert Opinion on Drug Safety
|March 7, 2014
PubMed
Summary

The U.S. Food and Drug Administration (FDA) faces challenges in regulating opioid analgesics, balancing pain management with public safety concerns regarding misuse and abuse. Inconsistencies in FDA decisions raise questions about transparency and effectiveness in opioid regulation.

More Related Videos

Comprehensive Analysis of Drug Response using the FLICK Assay
09:42

Comprehensive Analysis of Drug Response using the FLICK Assay

Published on: June 6, 2025

859
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

666

Related Experiment Videos

Last Updated: May 2, 2026

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery
09:38

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery

Published on: April 14, 2016

14.0K
Comprehensive Analysis of Drug Response using the FLICK Assay
09:42

Comprehensive Analysis of Drug Response using the FLICK Assay

Published on: June 6, 2025

859
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

666

Area of Science:

  • Pharmacology and Toxicology
  • Regulatory Science
  • Public Health Policy

Background:

  • The U.S. Food and Drug Administration (FDA) plays a crucial role in ensuring medication safety and efficacy.
  • Regulating opioid analgesics presents complex challenges due to the need to treat patients with severe pain while mitigating risks of misuse and abuse.

Discussion:

  • Recent FDA regulatory decisions reveal complexities in balancing patient needs with public safety concerns for opioid analgesics.
  • Inconsistencies, such as tamper-resistance requirements for some extended-release opioids but not others, and vague labeling changes, create ambiguity in appropriate use.
  • Postmarketing data collection requirements, while affirmed, may yield unclear results and unintended consequences.

Key Insights:

  • The FDA's regulatory approach to opioid analgesics demonstrates a complex balancing act between therapeutic use and public safety.
  • Specific decisions, including differential tamper-resistance mandates and revised indications, highlight inconsistencies in the FDA's strategy.
  • Concerns exist regarding the clarity and consistency of FDA's regulatory actions and data collection methods for opioid analgesics.

Outlook:

  • Continued scrutiny of FDA's regulatory framework for opioid analgesics is warranted.
  • Enhanced transparency and consistency in FDA decision-making are crucial for effective opioid risk management.
  • Future regulatory strategies should aim for clearer guidelines and more robust data collection to address the opioid crisis effectively.